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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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CHDI head scientist Pacifici: ‘hang on in the learning
roller coaster ride of Huntington’s disease clinical
trials’
With historic clinical trials now aiming for the first effective treatments for
Huntington’s disease, affected individuals and their families need to clearly
understand the news about these efforts and their implications.
That critical recommendation was offered by Robert Pacifici, Ph.D., the chief
scientific officer of the nonprofit HD-treatment-seeking CHDI Foundation, Inc.,
during an interview on the last day of the organization’s 15th Annual HD
Therapeutics Conference, held February 24-27 in Palm Springs, CA.
“Getting to this stage – which we’ve all so been hoping for – is still a bit of a
roller coaster ride,” Dr. Pacifici told me. “You have to be able stay in our seats and
weather the ups and downs. I think we’re well-poised for some great news, as
some of these trials hopefully report out. Even a whisper of efficacy would be just
amazing.”
However, there will also be “disappointments, where, despite our best attempts,
some of the things that showed so much promise didn’t end up meeting their
endpoints,” he cautioned. “But it’s going to be a learning roller coaster. So hang in
there. Don’t lose hope.”
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The HD-affected (and their caregivers) should keep informed about the trials by
consulting their physicians, attending meetings of patient organizations such as
the Huntington’s Disease Society of America (HDSA), and keeping abreast of
developments in such sources as HDBuzz.net and this blog, Dr. Pacifici advised.
Become knowledgeable, he urged, “so that you are not disproportionately spooked
or elated when these bits of information come out.”
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Featured conference speaker Christopher Austin, M.D., the director of the
National Center for Advancing Translational Sciences/National Institutes of
Health, presents part of the Drug Discovery, Development and Deployment Map
the research and pharmaceutical community must navigate in today's complex and
challenging scientific world (photo by Gene Veritas, aka Kenneth P. Serbin).
‘Genuinely interested’ in treating HD
Dr. Pacifici began the interview noting the excitement generated by the
conference and within the HD field, with a record 380 participants, overflow
seating, and more than 100 people turned away. However, CHDI’s goal ultimate
goal is not to host well-attended conferences, but to stop HD, he emphasized.
“There are that many people who are genuinely interested in presenting the results
and learning about the incredible developments that are unfolding in Huntington’s
disease drug discovery and development,” he said of the response to the
conference.
Dr. Pacifici also noted the very high quality of the presentations, in comparison
with the early years of the event.
“We’re batting 1,000 this time – every single talk very relevant,” he observed.
Considered science fiction a decade ago, the new technologies applied in HD
research are transforming the field and allowing for a more thorough analysis of
cells in the quest to understand the disease, he added.
Dr. Pacifici cited the example of whole-genome sequencing on individual brain
cells, which permits the reading of the DNA sequence of “every single gene in
there, and doing that thousands of times.”
You can watch my interview with Dr. Pacifici in the video below. For my video
album of the conference, please click here (and check back in the coming days as
I add videos).
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Hang on in the 'learning roller
coaster ride' of Huntington's disease clinical trials
from Gene Veritas

26:56

Hang on in the 'learning roller coaster ride' of Huntington's disease clinical trials
from Gene Veritas on Vimeo.
New understanding of the protein
Dr. Pacifici also discussed new research into the huntingtin protein presented at
the conference. Such research suggests that the protein might have a key role in
maintaining the integrity of the huntingtin gene and also in the way the gene
expands over time (known as somatic expansion), which researchers now see as a
key driver of the disease (click here to read more).
With this potential new finding, a single drug might be developed to counteract
the mutant protein by both reducing its quantity and preventing it from causing
somatic expansion, he speculated.
He pointed in particular to the presentation by Jeffrey Carroll, Ph.D.
A possible key biomarker
Dr. Pacifici also commented on the discussion around phosphodiesterase-10
(PDE-10). A PDE inhibitor was seen as a potential “Viagra for the brain” but
ultimately showed no improvement in a clinical trial run by the drug giant Pfizer.
However, PDE-10 might still play a role for the HD community as a biomarker
(sign of disease and/or effect of a treatment), Dr. Pacifici said.
“It is pretty uniquely expressed in the neurons that we know are affected by
Huntington’s disease, the medium spiny neurons,” he explained.
If PDE-10 decreases in HD because the gene is shut down or cells die or some
combination of both, and “if you had a molecule that bound to PDE10 and sent
out a signal, then you could know how much PDE10 was in that brain, and if it
was declining, that would mean that the disease was progressing.” Similarly, with
an effective therapy, “you would see PDE10 levels going up,” Dr. Pacifici added.
The U.S. Food and Drug Administration is unlikely to approve a drug based solely
on evidence from a biomarker, because it needs to see actual clinical benefits in
patients, Dr. Pacifici said. However, the biomarker could give a drug maker the
“confidence” that the “intervention is doing its job biologically and now it’s worth
waiting for the clinically meaning outcome.”
(The presentation by Steven A. McCarroll, Ph.D., of the Harvard Medical School,
included discussion of the role of PDE-10.)
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Above, Dr. Steven McCarroll answers a question from the audience after his
presentation on single-cell analysis of HD biology. Below, McCarroll lab
researchers Nora Reed (left) and Christopher Mullally with the lab's poster on
single-cell analysis, which took second prize in the poster competition (photos by
Gene Veritas).

The terrifying truth about drug development
Dr. Pacifici reflected on the in-depth talk by the conference’s featured speaker,
Christopher Austin, M.D., the director of the National Center for Advancing
Translational Sciences (NCATS) of the National Institutes of Health. NCATS,
founded in 2011, aims to speed the development of treatments and cures.
I asked Dr. Pacifici to comment on the phrase that struck me from Dr. Austin’s
presentation: “The hard work that nobody else wants to do.”
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Scientific research is “unsexy” and “difficult to understand,” but Dr. Austin
challenged the field to forge ahead, I observed.
“He painted a pretty bleak picture of how we’re sadly finding diminishing returns
on our investment,” Dr. Pacifici said regarding drug investigation in general. “In
other words, he kind of flipped around Moore’s law. Instead of things getting
better and faster, the more money we spend, the fewer treatments we see coming
out, especially for the harder neurological diseases.”
Dr. Austin presented to the audience what he called a “truly terrifying fact”: “The
number of new drugs approved per billion dollars spent, inflation-adjusted, has
gone down by half every nine years, since 1950.”
You can learn why this is so – and its very serious implications for HD – by
watching Dr. Austin’s presentation by clicking here.
The HD field hopes to be the exception and the model
Dr. Pacifici pointed to the difficult and complex challenges involved in drug
discovery, as illustrated by Dr. Austin.
Everybody wants to be the “star” that “made the compound that turned out to be
the cure,” Dr. Pacifici said. But imagine: the compound is there, but no patients
are available to do the clinical trial. Or patients participate, but researchers lacked
the “outcome measures to see whether people were actually getting better.” Or,
antibodies and assays needed to measure the samples derived from patients
weren’t there.
Those things are the not-so “sexy” but need to get done, he said.
The HD field will need to overcome the inertia of diminishing returns, Dr. Austin
emphasized. Deeply familiar with HD science, he believes that HD as a
monogenetic disease has the potential to do so and could serve as the model for
treating other, more common neurological disorders.
Dr. Pacifici agreed. He praised the HD research and biotech community not only
for its commitment to make sure that key elements of the drug-hunting process are
“proactively put in place,” but the “selflessness with which they are shared, so that
those don’t represent competitive advantages for one company or another. I think
everybody has come to the realization that this is a really hard problem. It’s no use
competing with each other. We’re going to have to help each other.”

At the start of his talk on huntingtin-lowering strategies, Ignacio Muñoz-Sanjuán,
Ph.D., a CHDI scientist and the co-founder of Factor-H, reminded the audience of
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the goal of the HD cause: to help individuals like Anyervi (in cap) and Brenda,
two youths from South America with juvenile HD (photo by Gene Veritas).
Posted by Gene Veritas at 11:06 PM
Labels: biomarkers , CHDI Foundation , Christopher Austin , clinical trials , HD
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